Review Article

**Human Immunodeficiency Virus Epidemic among People who Inject Drugs and Female Sex Workers in North Africa: A Systematic Review**

.

ABSTRACT

|  |
| --- |
| **Background:** Human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) remain major health problems worldwide, with high mortality and morbidity rates, particularly in developing countries. The United Nations Programme on HIV/AIDS (UNAIDS) reported that there were 38.4 million individuals globally who had HIV. Around 1.5 million new HIV infections were recorded in 2021, while approximately 650,000 individuals worldwide lost their lives due to AIDS-related illnesses. The prevalence of HIV in people who inject drugs (PWID) and female sex workers (FSWs) has not been widely investigated.  Information on the epidemiology of HIV infection among PWID and FSWs in the North Africa is limited. The aim of the present study was to review the status of the HIV epidemic among PWID and FSWs in North Africancountries by explaining HIV prevalence.  **Methods:** A comprehensive literature search was performed on studies related to the prevalence of HIV infection in PWID and FSWs published between 1990 and 2024 using search engines such as PubMed, Science-Direct, Google scholar.Reports that are entirely on North Africa were considered.  **Results:** A total of 3605 records were retrieved in the initial search, 11 relevant records HIV among PWID and FSWs were recognized and included in the study. The overall prevalence of HIV in PWID ranged from 0.15% to 87.1% and 0% to 15.7% in FSWs, respectively. Injection drug abuse and women engaged in sex work were commonly associated with HIV infection.  **Conclusion:** The findings of the this study showed that the prevalence of HIV among PWID and FSWs in North Africa is high. The execution of initiatives designed to improve sanitation infrastructure, elevate educational standards, and enhance socioeconomic situations is crucial for decreasing the prevalence of HIV infections among PWID and FSWs. |

*Kay words:**Human immunodeficiency virus****;*** *people who inject drugs; female sex workers; North Africa*

1. INTRODUCTION

Human immunodeficiency virus (HIV) is a member of the Lentivirus genus belonging to the Retroviridae family. In 1981, it was identified as the initial cause of the illness now referred to as acquired immunodeficiency syndromes (AIDS) [1, 2]. HIV is spread mainly from the body fluids of an infected person, including blood, breast milk, semen and vaginal fluids [3]. HIV infection is characterized by mild immune system alterations that occur before any symptoms or negative emotions appear. Before seroconversion, which occurs when an individual has just been exposed to HIV, this stage lasts for up to three months after infection. Although the course of an infection and the amount of time it takes for clinical signs to appear might vary widely from person to person, the disease typically advances rather slowly. The onset of progressive HIV illnesses and immunosuppressive symptoms takes several years after the first infection [4]. HIV targets cells of the human immune system, such as CD4+ T cells,macrophages, and dendritic cells. CD4+ cells play an important role in maintaining the immune system. After infection, HIV uses CD4+ cells as hosts to multiply and infect other cells. As a result, the body's CD4+ cell count decreases and the immune system shuts down completely. Rapid decline in CD4+ cells prevents HIV from progressing to AIDS [5]. Chronic HIV infection is causing a deficiency in cellular immunity. The unexpected emergence of opportunistic infections characterizes this final stage of HIV infection. The main contributors to HIV-related morbidity and death are these last ones. The use of cotrimoxazole and antiretroviruses can significantly lower the frequency of opportunistic infections and increase the life expectancy of HIV patients. The initiation of antiretroviral therapy for an individual with HIV is determined by their level of immune system weakness [6]. The sensitive enzyme immunoassays available today can identify antibodies as soon as one to two weeks following infection. Other tests are necessary to support antibody investigation(p24 antigen, PCR),corroboratepositiveantibody screens(Western blot, PCR), and give clinicians treating HIV-positive patients additional information (qualitative and quantitative PCR, genotyping) [7]. There are two types of HIV have been described: HIV-1 and HIV-2. Globally, HIV-1 infection is the leading cause of the AIDS pandemic, while the emergence of HIV-2 is concentrated in West African countries [8]. At present, HIV infection continues to be one of the most serious global health issues facing humans. According to statistics from the United Nations (UN), the global number of individuals living with HIVin 2021 tallied at approximately 38.4 million. Furthermore, an estimated 1.5 million new cases of HIV infections emerged. Additionally, in 2021, around 650,000 deaths were attributed to AIDS-related illnesses. HIV remains a major cause of illness and death in developing nations, including North African countries [9]. People who inject drugs (PWID) are at increased risk of HIV; worldwide, about 11 million people inject drug, and around 1 in 8 (or 1.4 million) of these people are living with HIV. In addition, 10% of new HIV infections worldwide are due to the use of injection drugs [10]. Globally, sex workers are facing a greater impact from the HIV pandemic [11]. Although HIV/AIDS is a silent and fatal disease, little is known about its infection among PWID and FSW in North African countries. Hence, The aim of this study was to assess the status of the HIV prevalence among PWID and FSWs in North Africa to help understanding of the HIV epidemiology in this part of the African continent.

2. methods

Present systematic review summarizes main results of the HIV epidemiology among PWID and FSWs in North Africa. A comprehensive literature search was performedusing PubMed, Science-Direct and Google Scholar, databases for articles published in English from 1990 until 2024. The data included in present review were primarily conducted in the countries of the North Africa. These data sources were recognized through a comprehensive search of pertinent studies and databases. The keywords used to question the databases included HIV in combination with prevalence, “PWID”, “FSWs”, as well as North Africa and country names. All articles were evaluated for pertinence before inclusion. The review involved all countries contained in the North Africa descriptions of the World Bank and WHO EMRO. These include Algeria, Libya, Egypt, Morocco, and Tunisia. In this article, the North Africa high-risk groups were including people who inject drugs (PWID) as well as female sex workers (FSWs).

3. results

A total of 3605 records were identified from three databases. Duplicates studies were identified and removed, leaving 166 potential records, after review of titles and abstractsrecords were excluded based on selection criteria, and a total of11 reports on the prevalence of HIV among PWID and FSWs covering 4 countries were included. The review process is presentedin Figure1.

3605articles were found in the electronic search through PubMed, ScienceDireact, Google scholar

Screening titles and abstracts

3345 articles and 94 abstracts excluded

11 articles included:

5 studiesfrom Egypt

2studiesfrom Libya

2studiesfrom Morocco

2studiesfrom Tunisia

**Figure 1.** Flowchart of study selection

Eight studies recorded HIV positive among PWID, 5 recorded the HIV positive among FSWs Sample sizes ranged from 113 to 12,981 PWID,and 69 to1447 FSWs. PWID and FSWsdata were obtainablefor 4 of the 5 NA countries. No studies were available for Algeria. Egypt contributed the largest number of data points of HIV prevalence measures where, there were 5 studies from Egypt, 2 from Tunisia, Morocco, and Libya, respectively.

The prevalence of HIV across the key populations such as PWID and FSWs reported by the 11 studies was range between 0 and 87.1%. When divided according to population categories,injecting drugs is a primary way HIV is transmitted globally [10]. Study population was HIV prevalence ranged from 0.15% in a study from Egypt to87.1**%** in a study fromLibya(Table 1). The median HIV prevalence among PWID in all studies was 0.91%. Sexual hazard behavior associated with HIV infection among FSWs, The country-specific estimate FSWs ranged from 0% in Tunisia to 15.7% in Libya. Egypt and Morocco had a prevalence estimate < 9% (Table 2). The median HIV prevalence among FSWs in all studies was 1.25%.

Twostudies were found in this review that recorded HIV/HCV and HIV/HBV coinfection, the prevalence of HIV/HCV and HIV/HBV co-infections among PWID was 83.2% and 3.7%, respectively. Beside,the prevalence of HIV/HCV and HIV/HBV co-infections among FSWs was 3.7%and0%, respectively.

**Table 1.** Studies reporting HIV prevalence among people who inject drugs (PWID) across the North Africa

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Study/references** | **Year** | **Sampling location** | **Study**  **population** | **Age group** | **HIV prevalence among PWID** |
| Mirzoyan L,at al [12] | 2013 | Libya | 328 | 15-≥50 | 87.1% |
| Cherif S at al [13] | 2010 | Egypt | 413 | 18-65 | 1%-4 |
| Watts DM at al [14] | 1993 | Egypt | 1961 | Any age | 0.15% |
| Anan A at al [15] | 2024 | Egypt | 146 | 11-50 | 31.5% |
| Wahdan I at al [16] | 2012 | Egypt | 338 | <25->45 | 12.4% |
| Martinez S at al [17] | 2018 | Egypt | 604 | 18->36 | 10.6% |
| Ghrabi A at al [18] | 2018 | Tunisia | 113 | 32-47 | 10% |
| Elmir E at al [19] | 2002 | Morocco | 12981 | 30-≥40 | 11.1% |

**Table 2.** Studies reporting HIV prevalence among female sex workers (FSWs) across the North Africa

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Study/references** | **Year** | **Sampling location** | **Study**  **population** | **Age group** | **HIV prevalence among FSWs** |
| Johnston L at al [20] | 2016 | Morocco | 1447 | 18 ≥ | 8.3% |
| Znazen A at al [21] | 2010 | Tunisia | 188 | 14-≥34 | 0% |
| Valadez JJ,at al [22] | 2013 | Libya | 69 | 15-≥50 | 15.7% |
| Watts DM at al [14] | 1993 | Egypt | 349 | Any age | 0% |
| Wahdan I at al [16] | 2012 | Egypt | 338 | <25-45+ | 5.9% |

**4. DISCUSSION**

HIV infection among PWID and FSWs continues to be a major public health issue worldwide [12]. Understanding the epidemiological characteristics of HIVinfection is crucial and beneficial in defining the implications and problems of the infection. Injecting drugs is a primary way HIV is transmitted globally [10]. The findings revealed that the HIV prevalence among North African PWID population groups ranged from 0% to 87.1%, This results is higher than the before estimates of global prevalence [23, 24]. It is also higher than the findings of studies conducted in Europe [25,26,27],China [28] Bangladesh [29]andBrazil [30]. By contrast, it is relatively low compared with other studies reported from USA [31],and Estonia [32]. The differences that were noticed in HIV prevalence among studies, nations, and areas could arise from diverse factors like compliance with prevention methods and variations in community spread. In this study, HIV prevalence among PWID is high in the northern countries of Africa, particularly Libya [12]. This occurrence can be ascribed to its geographical positioning, which borders three sub-Saharan nations, along with socio-political challenges that have significantly facilitated the spread of HIV and hindered the adherence to HIV control measures. These results highlight a need for continuing prevention of HIV transmission among PWID.

The HIV epidemic, similar to other epidemics, arises within a intricate social setting. Social norms impacting transmission include sexual behaviors. Between 75 and 85 percent of the approximately 28 million HIV infections that have happened thus far are due to transmission through sexual contact [33]. Concerning the investigation of HIV andrelated sexual risk like sex work,this systematic review shows that the HIV prevalence amongst North African FSWs population groups ranged from 0% to 15.7%. These outcomes are similar to numerous other systematic reviews conducted [34, 35]. However, low compared to what is observed in India [36], Kenya [37]. Additionally, it is higher than the results of studies conducted in China [38], Central America [39], and the and the Democratic Republic of the Congo [40].

Women engaging in sex work networks appear to be the main drivers of considerable HIV transmission in Libya, Morocco, and Egypt, which may attributed to the extensive scale of commercial sex networks in these environments, coupled with the elevated levels of hazard manners exhibited within these networks.FSWs and their male clients are at high hazardous for HIV and have been significant in starting the epidemic in many African countries [41].

The HIV epidemic is very fluid and has expanded quickly; nearly every country worldwide is impacted. However, prevalence investigations have been conducted on a global level to gain understanding of HIV epidemiology. Monitoring prevalence changes is crucial for predicting pandemic evolution and developing a successful public health strategy [42].

Situation in North Africa and the Middle East regarding HIV/AIDS: according to statistics from the United Nations (UN), around 180,000 people were estimated to be living with HIV, approximately 14000 people became newly infected with HIVV. Furthermore, roughly 5100 fatalities were linked to diseases related to AIDS in 2021 [9]. Sub-Saharan Africa, this region is the most heavily affected by HIV worldwide, accounting for 52.6 million people living with HIV and 42000 of AIDS deaths in 2021 [9]. This region borders North Africa, and many illegal immigrants come from it to north African countries. Therefore, individuals in communities with HIV may not know they are infected or carry the virus, leading to potential transmission to family members or other people.

On the basis of the geographical countries of North Africa, the results indicated that Libya [12], Egypt [15], Morocco [19] and Tunisia [18], respectively had higher prevalence HIV among PWID. Moreover, prevalence estimates at the country level indicate a high burden of infection in Libya [22], Morocco [20] and Egypt [16], respectively, among FSWs. The observed variation in the estimates of HIV prevalence among FSWs across various countries may be partially attributed to the diverse risk factors and spread pathways present in each nation. These results emphasize a continuous need for ongoing prevention of HIV spread among FSWs between North African countries.

In Africa, despite the high HIV prevalence, the reported occurrence of HIV infection among PWID and FSWs in North Africa was considerably lower compared with South Africa [43,44].

The North Africa region is still lacks sufficient HIV epidemiological information, leading to debates regarding the epidemic's prevalence in this part of the globe. It's crucial to have current HIV prevalence data for North African countries to understand the virus's spread. Hence, additional monitoring of HIV prevalence is necessary to evaluate and track the escalating HIV impact [45].

The environments where the HIV pandemic is happening are becoming more varied. The epidemics are primarily influenced by social, structural, and population-level risks and protections, which in turn affect the individual risks of HIV infection [46].

The field of HIV prevention is constantly changing, and there is now discussion about the potential for worldwide virtual eradication of HIV [47]. Mitigation of HIV disease and pioneering strategies will expected be required to decrease HIV prevalence in North Africa,wherethere might be restrictions on getting health care and accessing resources. The suitable approach can vary from one country to another and is additionally have to be justifiably focused on prevention of HIV transmission. While countries must focus on addressing the underlying causes of HIV exposure risk, the main emphasis should be on addressing the immediate factors that increase individuals' risk of HIV exposure, as dealing with structural factors is time-consuming and outside the purview of the public health sector. Hence, there is an opportunity for prevention that should not be missed to control the epidemic in this region [45].

This systematic review offers the latest extensive assessment of HIV prevalence by carefully evaluating existing literature. When interpreting results, it's vital to consider and navigate through various constraints in order to gain a comprehensive and robust understanding of the outcomes. The primary limitations come from the data that is currently available, with a scarcity of studies on prevalence. Despite these limitations, the present systematic review demonstrated that there is a significant burden of HIV infection in PWID and FSWs in most of the North African countries. However, additional investigation is required to fill the knowledge gaps.

5. Conclusion

The findings of this report provides a comprehensive overview of the prevalence of HIV among PWID and FSWs. Variation in prevalence of HIV observed in different regions in North Africa. As the HIV pandemic is still evolving, more studies need to be conducted in this part of the African continent to comprehend the right burden of the illness. Studies in this region need to take into consideration societal and institutional factors. The extensive programs of monitoring of HIV prevalence are necessary to prevent these high-risk groups from further spreading the infection of HIV. This review demonstrates epidemiological HIV infection in PWID and FSWs. These data can be used to develop customized strategies for eradicating the prevalence of HIV in the North African regions.

Consent

Not applicable

Ethical approval

Not applicable

References

1- Gruters RA, Neefjes JJ, Tersmette M, de Goede RE, Tulp A, Huisman HG, Miedema F, Ploegh HL. Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature. 1987;330(6143):74-77.

2. Fauci AS. The AIDS epidemic-considerations for the 21st century. N Engl J Med. 1999;341(14):1046-1050.

3- WHO. HIV and AIDS. https://www.who.int/news-room/fact-sheets/detail/hiv-aids 2024

4- Naif HM. Pathogenesis of HIV infection. Infec Dis Rep 2013; 5:s1e6

5- Yousaf MZ, Zia S, Babar ME, Ashfaq UA. The epidemic of HIV/AIDS in developing countries; the current scenario in Pakistan. Virology Journal 2011;8:401.

6- Comlan DA, Cossi AA, Angelo AC, Kadidjatou S, Serge A, Séraphin A, Jivather D, Francis TT, Zannou Djimon Marcel, Gabriel A, Fabien H. Clinical and Immunological Characteristics in HIV-Infected Patients at the Treatment Initiation at the University Hospital of Parakou (Benin). Open Journal of Immunology 2017;7:51-58

7- Fearon M. The laboratory diagnosis of HIV infections. Can J Infect Dis Med Microbiol 2005;16(1):26-30.

8-Campbell-Yesufu OT, Gandhi RT, Update on Human Immunodeficiency Virus (HIV)-2 Infection. Clin Infec Dis 2011;52:780–787

9- UNAIDS. Global HIV & AIDS statistics. 2022. Fact sheet

http: //[www.communications@unaids.org](http://www.communications@unaids.org)/en/resources/campaigns/global report 2021/ fact sheet

10-WHO. Global HIV, Hepatitis and STIs Programmes: People who inject drugs.

https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/populations/people-who-inject-drugs, 2024

11- WHO. Guidelines: prevention and treatment of HIV and other sexually transmitted infections for sex workers in low- and middle-income countries. Geneva: World Health Organization, 2012

12- Mirzoyan L, Berendes S, Jeffery C, Thomson J, Ben Othman H, Danon L, Turki AA, Saffialden R, Valadez JJ. New evidence on the HIV epidemic in Libya: why countries must implement prevention programs among people who inject drugs. J Acquir Immune Defic Syndr. 2013;62(5):577-83.

13- Soliman C, Rahman IA, Shawky S, Bahaa T, Elkamhawi S, El Sattar AA, Oraby D, Khaled D, Feyisetan B, Salah E, El Taher Z, El Sayed N. HIV prevalence and risk behaviors of male injection drug users in Cairo, Egypt. AIDS. 2010;24 Suppl 2:S33-8.

14- Watts DM, Constantine NT, Sheba MF, Kamal M, Callahan JD, Kilpatrick ME. Prevalence of HIV infection and AIDS in Egypt over four years of surveillance (1986-1990). J Trop Med Hyg. 1993;96(2):113-117.

15- Anan AM Alzahaby AA, Ghazy A, Abdelrazik OM. Clinico-Epidemiological Study of HIV Patients in El Beheira Governorate. International Journal of Medical Arts, 2024, 6.7: 4627-4634.‏

16- Wahdan I, Wahdan A, El Gueneidy M, Abd El Rahman I. Prevalence and determinants of condom utilization among people living with HIV/AIDS in Egypt. East Mediterr Health J. 2013;19(12):967-74..‏

17- Martinez S, Roess AA, Ruiz MS, Bakhoum A, El-Kharrat E. Cross-Sectional Comparison of Behavioral Risk Factors for HIV/HCV in People Who Inject Drugs (PWID) in Egypt. 2018.‏

18- Ghrabi A, Zaied S, Turki JK, Chamakh A, Taieb SB, Bouarrouj S. HIV and hepatitis C virus infections and associated risk behaviours among injecting drug users attending a syringe service program: a cross-sectional study in Tunis, Tunisia. J Vir Eradication, 2018;4: 24-25.‏

19- Elmir E, Nadia S, Ouafae B, Rajae M, Amina S, Rajae el A. HIV epidemiology in Morocco: a nine-year survey (1991-1999). Int J STD AIDS. 2002;13(12):839-42.

20- Johnston LG, Bennani A, Latifi A, Oumzil H, El-Omari B, El-Rhoufrani F, Ouarsas L, Alami K, El-Rhilani H. Using Respondent-Driven Sampling to Estimate HIV and Syphilis Prevalence Among Female Sex Workers in Agadir, Fes, Rabat and Tangier, Morocco. SexTransm Infec. 2013; 89:Suppl 1: A180-A180.‏

21- Znazen A, Frikha-Gargouri O, Berrajah L, Bellalouna S, Hakim H, Gueddana N, Hammami A. Sexually transmitted infections among female sex workers in Tunisia: high prevalence of Chlamydia trachomatis. Sex Transm Infect. 2010;86(7):500-505.

22- Valadez JJ, Berendes S, Jeffery C, Thomson J, Ben Othman H, Danon L, Turki AA, Saffialden R, Mirzoyan L. Filling the Knowledge Gap: Measuring HIV Prevalence and Risk Factors among Men Who Have Sex with Men and Female Sex Workers in Tripoli, Libya. PLoS One. 2013 Jun 19;8(6):e66701.

23- Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, Wodak A, Panda S, Tyndall M, Toufik A, Mattick RP; 2007 Reference Group to the UN on HIV and Injecting Drug Use. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008 Nov 15;372(9651):1733-1745.

24- Rashti R, Sharafi H, Alavian SM, Moradi Y, Mohamadi Bolbanabad A, Moradi G. Systematic Review and Meta-Analysis of Global Prevalence of HBsAg and HIV and HCV Antibodies among People Who Inject Drugs and Female Sex Workers. Pathogens. 2020 May 31;9(6):432.

25- Wenz B, Nielsen S, Gassowski M, Santos-Hövener C, Cai W, Ross RS, Bock CT, Ratsch BA, Kücherer C, Bannert N, Bremer V, Hamouda O, Marcus U, Zimmermann R; DRUCK Study group. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14). BMC Public Health. 2016; 5:16(1):927

26- Handanagic S, Bozicevic I, Civljak M, Dominkovic Z, Sevic S, Barbaric J, Nemeth Blazic T, Dakovic Rode O, Begovac J. HIV and hepatitis C prevalence, and related risk behaviours among people who inject drugs in three cities in Croatia: Findings from respondent-driven sampling surveys. Int J Drug Policy. 2016;32:57-63.

27- Hatzakis A, Sypsa V, Paraskevis D, Nikolopoulos G, Tsiara C, Micha K, Panopoulos A, Malliori M, Psichogiou M, Pharris A, Wiessing L, van de Laar M, Donoghoe M, Heckathorn DD, Friedman SR, Des Jarlais DC. Design and baseline findings of a large-scale rapid response to an HIV outbreak in people who inject drugs in Athens, Greece: the ARISTOTLE programme. Addiction. 2015;110(9):1453-67.

28- Zhang Y, Shan H, Trizzino J, Ruan Y, Beauchamp G, Mâsse B, Ma J, Gu Y, He Y, Rui B, Wang J, Poundstone K, Jiang Y, Brooks Jackson J, Shao Y. Demographic characteristics and risk behaviors associated with HIV positive injecting drug users in Xinjiang, China. J Infect. 2007;54(3):285-290.

29- Azim T, Chowdhury EI, Reza M, Faruque MO, Ahmed G, Khan R, Rahman M, Pervez MM, Jana S, Strathdee SA. Prevalence of infections, HIV risk behaviors and factors associated with HIV infection among male injecting drug users attending a needle/syringe exchange program in Dhaka, Bangladesh. Subst Use Misuse. 2008;43(14):2124-44.

30- Oliveira-Filho AB, Silva FQ, Santos FJA, Cardoso YMN, Di Miceli JFF, Resque RL, Silva-Oliveira GC, Martins LC, Pinheiro LML, Machado LFA, Pinto AR, Lemos JAR, Fischer B, Kupek E. Prevalence and risk factors for HIV-1 infection in people who use illicit drugs in northern Brazil. Trans R Soc Trop Med Hyg. 2020 7;114(3):213-221..‏

31- Peters PJ, Pontones P, Hoover KW, Patel MR, Galang RR, Shields J, Blosser SJ, Spiller MW, Combs B, Switzer WM, Conrad C, Gentry J, Khudyakov Y, Waterhouse D, Owen SM, Chapman E, Roseberry JC, McCants V, Weidle PJ, Broz D, Samandari T, Mermin J, Walthall J, Brooks JT, Duwve JM. Indiana HIV Outbreak Investigation Team. HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014-2015. N Engl J Med. 2016;375(3):229-39

32- Platt L, Bobrova N, Rhodes T, Uusküla A, Parry JV, Rüütel K, Talu A, Abel K, Rajaleid K, Judd A. High HIV prevalence among injecting drug users in Estonia: implications for understanding the risk environment. AIDS. 2006;20(16):2120-3.

33- Royce RA, Seña A, Cates W Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med. 1997 Apr 10;336(15):1072-1078.‏

34- Paz-Bailey G, Noble M, Salo K, Tregear SJ. Prevalence of HIV Among U.S. Female Sex Workers: Systematic Review and Meta-analysis. AIDS Behav. 2016 ;20(10):2318-2331

35- Leili A, NargesK, Hamid S. Prevalence of HIV infection among female sex workers in the Eastern Mediterranean Region countries: a systematic review. HIV & AIDS Review. Int J HIV-Related Problems, 2021, 20.4: 235-256.‏

36- Wayal S, Cowan F, Warner P, Copas A, Mabey D, Shahmanesh M. Contraceptive practices, sexual and reproductive health needs of HIV-positive and negative female sex workers in Goa, India. Sex Transm Infect. 2011;87(1):58-64

37-Luchters S, Chersich MF, Rinyiru A, Barasa MS, King'ola N, Mandaliya K, Bosire W, Wambugu S, Mwarogo P, Temmerman M. Impact of five years of peer-mediated interventions on sexual behavior and sexually transmitted infections among female sex workers in Mombasa, Kenya. BMC Public Health. 2008;8:143

38- Wang H, Chen RY, Ding G, Ma Y, Ma J, Jiao JH, Wu Z, Sharp GB, Wang N. Prevalence and predictors of HIV infection among female sex workers in Kaiyuan City, Yunnan Province, China. Int J Infect Dis. 2009;13(2):162-9.

39- Soto RJ, Ghee AE, Nunez CA, Mayorga R, Tapia KA, Astete SG, Hughes JP, Buffardi AL, Holte SE, Holmes KK. Estudio Multicentrico Study Team. Sentinel surveillance of sexually transmitted infections/HIV and risk behaviors in vulnerable populations in 5 Central American countries. J Acquir Immune Defic Syndr. 2007;46(1):101-11

40-Vandepitte JM, Malele F, Kivuvu DM, Edidi S, Muwonga J, Lepira F, Abdellati S, Kabamba J, Van Overloop C, Buvé A. HIV and other sexually transmitted infections among female sex workers in Kinshasa, Democratic Republic of Congo, in 2002. Sex Transm Dis. 2007 ;34(4):203-8

41- Hunter DJ. AIDS in sub-Saharan Africa: the epidemiology of heterosexual transmission and the prospects for prevention. Epidemiology, 1993, 4.1: 63-72.‏

42- Bokazhanova A, Rutherford GW. The epidemiology of HIV and AIDS in the world. Collegium antropologicum, 2006, 30.2: 3-10.‏

43- Jones HS, Anderson RL, Cust H, McClelland RS, Richardson BA, Thirumurthy H, Malama K, Hensen B, Platt L, Rice B, Cowan FM, Imai-Eaton JW, Hargreaves JR, Stevens O. HIV incidence among women engaging in sex work in sub-Saharan Africa: a systematic review and meta-analysis. medRxiv. 2023: 23297108.

44- Asher AK, Hahn JA, Couture MC, Maher K, Page K. people who inject drugs, HIV risk, and HIV testing uptake in sub-Saharan Africa. J Assoc Nurses AIDS Care. 2013 ;24(6):e35-44.

45- Abu-Raddad LJ, Hilmi N, Mumtaz G, Benkirane M, Akala FA, Gabriele Riedner G, Tawil O, Wilson D. Epidemiology of HIV infection in the Middle East and North Africa. AIDS 2010, 24 (suppl 2):S5-S23

46- Beyrer C. HIV Epidemiology Update and Transmission Factors: Risks and Risk Contexts-16th International AIDS Conference Epidemiology Plenary. Clin Infec Dis 2007; 44:981-987

47- Mutevedzi PC, Newell ML. The changing face of the HIV epidemic in sub-Saharan Africa. Trop Med Int Health. 2014;19:9:1015-1028